Teva-Excellence, Teva-Care

Environmental Responsibility

Legater og donationer

​Her finder du en oversigt over legater og donationer uddelt af Teva Denmark A/S

The Danish Multiple Sclerosis Treatment Registry

Projektets navn
The Danish National Multiple Sclerosis Database COMPOS
 
Legatansøger
The Danish Multiple Sclerosis Treatment Registry
 
Projekttype
Database adaptation and implementation
 
Baggrund

Currently disease modifying treatment is monitored and registered in The Danish Multiple Sclerosis Treatment Registry, established in 1996 when the first immunomodulatory treatment was approved in Denmark. The task of the registry is to monitor the quality of the immunomodulatory treatment of multiple sclerosis (MS) in all neurological departments in Denmark and to collect data for research projects. Prospective clinical parameters are reported for all MS patients in Denmark who receive immunomodulatory or immunosuppressive treatment. This data serves as background for the yearly report from the Danish Multiple Sclerosis Group (DMSG), to ensure a high and fairly uniform standard in the treatment of relapsing-remitting multiple sclerosis in the fourteen Danish MS clinics and to disclosure of unmet needs.

 

The current platform for The Danish Multiple Sclerosis Treatment Registry does not fulfill the demands of a modern clinical database, due to a lack of active visual interface. Thus, the system is of no help in the daily clinical practice and for individual patient management, as data cannot be easily retrieved.
 
Formål

The Danish Multiple Sclerosis Group (DMSG) has decided that The Danish Multiple Sclerosis Treatment Registry should adapt the Swedish MS database, called COMPOS.

 

When the platform has been completed, all data from the recent system called Klinisk Måle System (KMS), will be transferred to The Danish National Multiple Sclerosis Database COMPOS.  The new platform will have a significant impact on the clinical management of MS-patients, as the interface permits a graphical visualization of the disease course, relapse history and easy access to all relevant paraclinical data. This new platform will also ease the identification of candidates for clinical trials, and allow recordings from not only patients on disease modifying treatment but all patients in the MS clinics.
 
Parternes rolle i projektet

The Danish Multiple Sclerosis Treatment Registry: Forestår alle aktiviteter i projektet.

Teva Denmark A/S: Udelukkende økonomisk støtte.

 
 
Tidsramme
2014-15
 
Beløb
150.000 DKK
 
Eventuel ikke-finansiel støtte
Ingen